Alphatec Holdings, Inc. develops medical technology for spine surgery, with a business centered on procedural spine solutions, surgical instrumentation, imaging, navigation and informatics. Company updates commonly address surgical revenue trends, EOS revenue, surgeon adoption, product launches such as Valence and EOS Insight, and the continued development of its InformatiX platform through subsidiaries including Alphatec Spine, EOS imaging and SafeOp Surgical.
Recurring developments also include financing actions, credit-facility activity, strategic partnerships tied to spinal fusion and regenerative technology, profitability metrics and annual outlook updates. Governance items, including board composition changes, appear alongside operating results and capital-structure announcements.
Alphatec Holdings (ATEC), a spine surgery solutions provider, announced its participation in four upcoming investor conferences:
- RBC West Coast Medical Device Bus Tour on August 14, 2024
- Piper Sandler MedTech and Diagnostics California Bus Tour on August 21, 2024
- Morgan Stanley Global Healthcare Conference on September 4, 2024
- Wells Fargo Healthcare Conference on September 5, 2024
Live webcasts, if available, will be accessible on ATEC's Investor Relations website. Additionally, ATEC granted 44,772 restricted stock units (RSUs) to 22 new non-executive employees as employment inducement. These RSUs will vest over four years and fully upon a change of control.
ATEC (Nasdaq: ATEC) has launched EOS Insight, an innovative end-to-end spine surgery platform powered by EOSedge scans and AI. The first EOS Insight-informed surgeries were successfully performed at OrthoIndy Hospital. This groundbreaking platform leverages AI to provide important information throughout multiple stages of spine care, including:
- AI-driven alignment calculation
- 3D-surgical planning simulations
- Patient-specific rods
- Intra-operative reconciliation
- Post-operative analytics
EOS Insight aims to modernize spine surgery by replacing archaic clinical practices and improving patient outcomes. The platform's ability to automate processes and integrate alignment data into surgical plans positions ATEC as a potential standard-bearer in spine care.
Alphatec Holdings (Nasdaq: ATEC) announced it will report its Q2 2024 financial results on July 31, 2024, after the market close. A live webcast will be hosted at 1:30 p.m. PT / 4:30 p.m. ET, accessible through the Investor Relations section of the company's website. Participants can dial into the webcast after registering online, and a replay will be available for twelve months.
In related news, ATEC's independent Compensation Committee approved inducement grants for 30 new employees, totaling 47,112 restricted stock units (RSUs). These RSUs will vest annually over four years, contingent on continuous employment, and will fully vest upon a change of control of the company.
Alphatec Holdings, Inc. (Nasdaq: ATEC) reported a 27% growth in total revenue to $138 million, with 30% increase in surgical revenue. Adjusted EBITDA margin expanded by 450 basis points. Full-year revenue and adjusted EBITDA guidance raised to $601 million and $23 million respectively. The company experienced growth in surgical revenue, surgeon adoption, and U.S. footprint expansion. Ending cash balance was $144 million. Non-GAAP gross margin was 71%. The CEO expressed confidence in the company's future growth potential.
Alphatec Holdings, Inc. (Nasdaq: ATEC) will be participating in several investor conferences in May and June 2024. The company also granted 14,024 restricted stock units to new employees as an inducement to accepting employment, which will vest in equal annual installments on each of the first four anniversaries of the grant date, contingent on the recipient's continuous employment with ATEC.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.